mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

被引:289
作者
Cafri, Gal [1 ,2 ]
Gartner, Jared J. [1 ]
Zaks, Tal [3 ]
Hopson, Kristen [3 ]
Levin, Noam [1 ]
Paria, Biman C. [1 ]
Parkhurst, Maria R. [1 ]
Yossef, Rami [1 ]
Lowery, Frank J. [1 ]
Jafferji, Mohammad S. [1 ]
Prickett, Todd D. [1 ]
Goff, Stephanie L. [1 ]
McGowan, Christine T. [1 ]
Seitter, Samantha [1 ]
Shindorf, Mackenzie L. [1 ]
Parikh, Anup [1 ]
Chatani, Praveen D. [1 ]
Robbins, Paul F. [1 ]
Rosenberg, Steven A. [1 ]
机构
[1] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
[2] Sheba Med Ctr, Derech Sheba 2, Ramat Gan, Israel
[3] Moderna Inc, Cambridge, MA USA
关键词
TUMOR; IDENTIFICATION; LYMPHOCYTES;
D O I
10.1172/JCI134915
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND. Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have demonstrated that T cells recognizing neoantigens are present in most cancers and offer a specific and highly immunogenic target for personalized vaccination. METHODS. We recently developed a process using tumor-infiltrating lymphocytes to identify the specific immunogenic mutations expressed in patients' tumors. Here, validated, defined neoantigens, predicted neoepitopes, and mutations of driver genes were concatenated into a single mRNA construct to vaccinate patients with metastatic gastrointestinal cancer. RESULTS. The vaccine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detected before vaccination. Furthermore, we were able to isolate and verify T cell receptors targeting KRAS(G12D) mutation. We observed no objective clinical responses in the 4 patients treated in this trial. CONCLUSION. This vaccine was safe, and potential future combination of such vaccines with checkpoint inhibitors or adoptive T cell therapy should be evaluated for possible clinical benefit in patients with common epithelial cancers.
引用
收藏
页码:5976 / 5988
页数:13
相关论文
共 21 条
[21]   Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer [J].
Zacharakis, Nikolaos ;
Chinnasamy, Harshini ;
Black, Mary ;
Xu, Hui ;
Lu, Yong-Chen ;
Zheng, Zhili ;
Pasetto, Anna ;
Langhan, Michelle ;
Shelton, Thomas ;
Prickett, Todd ;
Gartner, Jared ;
Jia, Li ;
Trebska-McGowan, Katarzyna ;
Somerville, Robert P. ;
Robbins, Paul F. ;
Rosenberg, Steven A. ;
Goff, Stephanie L. ;
Feldman, Steven A. .
NATURE MEDICINE, 2018, 24 (06) :724-+